

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 6185)**

**INSIDE INFORMATION**

**INTENTION TO ISSUE GLOBAL DEPOSITORY RECEIPTS AND  
APPLY FOR ADMISSION TO LISTING ON SIX SWISS EXCHANGE AG**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

**THE PROPOSED ISSUANCE AND ADMISSION OF GDRS**

The board (the “**Board**”) of directors of the Company wishes to inform the shareholders and potential investors of the Company that, to further broaden the Company’s international financing channels, enhance the Company’s international brand and image, meet the Company’s overseas business development needs, and promote the Company’s globalization strategy, the Company intends to issue Global Depository Receipts (“**GDRs**”) and apply for the admission of the same to listing on the SIX Swiss Exchange AG (the “**Proposed Issuance and Admission of GDRs**”).

**BENEFITS AND REASONS FOR THE PROPOSED ISSUANCE AND ADMISSION OF GDRS**

**I. Promoting the Company’s Globalization Strategy**

The Company is dedicated to research and development, manufacturing and commercialization of innovative vaccine products that meet PRC and international standards. The Company’s COVID-19 vaccine products have been granted emergency use authorization and/or conditional approval in many overseas countries and has been issued an emergency use listing of World Health Organization. The Proposed Issuance and Admission of GDRs will further promote the Company’s globalization strategy, enhance the Company’s overseas reputation and expand overseas business, clinical trial selections and business cooperation opportunities.

## II. Leveraging Capital Market Resources

The Proposed Issuance and Admission of GDRs is a key step for the Company to actively respond to the domestic capital market policy, deepen the inter-connection of the Sino-European capital markets, and promote the economic development through offshore capital markets. The Company will leverage the favorable opportunity and policy to achieve direct connection with offshore capital markets, enhance the Company's overseas brand awareness, enhance multi-channel financing capabilities, and raise sufficient funds and financial resources for the Company's globalization strategy development.

## III. Improving Corporate Governance

By issuance and listing of the GDRs, the Company will be able to attract additional offshore professional institutional investors and investors in the industry, which will optimize the Company's share capital structure and further improve the transparency and standard of corporate governance of the Company, thereby providing a solid corporate governance structure for the Company to achieve high quality development.

**Shareholders and potential investors should note that, as of the date of this announcement, the issuance size, implementation plans, and use of proceeds of the Proposed Issuance and Admission of GDRs are still under discussion. The Proposed Issuance and Admission of GDRs and the relevant matters are subject to the approval of the Board, the approval of shareholders' meeting of the Company, as well as the approvals of the relevant PRC and foreign regulatory authorities including the China Securities Regulatory Commission and SIX Swiss Exchange AG. Such approvals are prerequisite to the implementation of the Proposed Issuance and Admission of GDRs, and there is uncertainty as to whether and when such approvals will be obtained. In addition, the Proposed Issuance and Admission of GDRs is subject to the risk of suspension or termination due to international environment, market conditions, timing of financing, regulatory requirement or other reasons. Accordingly, the Proposed Issuance and Admission of GDRs may or may not proceed as contemplated or at all. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company. Further announcement(s) will be made as and when appropriate.**

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, January 10, 2023

*As of the date of this announcement, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive Directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.*